mattjeacock
Cell platform company Ginkgo Bioworks (NYSE:DNA) announced Wednesday it expanded a strategic partnership with Novo Nordisk (NVO) (OTCPK:NONOF) to improve the production of the Danish pharma giant's key drugs, including those targeted at diabetes and obesity.
In addition to discovering manufacturing solutions, the companies will collaborate on technology exploration across Novo's (NVO) entire product portfolio and some of its early pipeline projects. Per the terms of a framework agreement, the expanded collaboration is expected to last five years initially.
"We look forward to leveraging Ginkgo's synthetic biology platform across our R&D pipeline, from discovery through new ways of manufacturing, in this broader strategic partnership," Novo Nordisk's (NVO) Chief Scientific Officer remarked.
Additionally, on Wednesday, Ginkgo (DNA) announced that the Bill & Melinda Gates Foundation had awarded it a grant to develop an open-access, AI-driven measles forecasting model.